Sarpogrelate Delivered via Osmotic Pump Improves Residual Hearing Preservation After Cochlear Implantation.

IF 3.4 3区 医学 Q1 OTORHINOLARYNGOLOGY
Jungho Ha, Siung Sung, Jongmoon Jang, Young Sun Kim, Seongjun So, Jeong Hyeon Yun, Yun-Hoon Choung, Jeong Hun Jang
{"title":"Sarpogrelate Delivered via Osmotic Pump Improves Residual Hearing Preservation After Cochlear Implantation.","authors":"Jungho Ha, Siung Sung, Jongmoon Jang, Young Sun Kim, Seongjun So, Jeong Hyeon Yun, Yun-Hoon Choung, Jeong Hun Jang","doi":"10.21053/ceo.2024.00354","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the effects of sarpogrelate, a selective 5-hydroxytryptamine (5-HT) 2A receptor antagonist, on the preservation of residual hearing and modulation of inflammatory responses following cochlear implantation (CI) in an animal model.</p><p><strong>Methods: </strong>The damaging effects of CI were simulated in male albino guinea pigs using a dummy electrode. Animals were allocated to three groups: control (n=12, dummy electrode insertion only), SPG-1004 (n=7, low-capacity pump delivering sarpogrelate), and SPG-2004 (n=6, high-capacity pump delivering sarpogrelate). Sarpogrelate was administered via osmotic pumps at two different volumes, and its effects on hearing thresholds, histological outcomes, and expression of inflammation-related genes were assessed. Hearing was evaluated using auditory brainstem response (ABR) thresholds measured at baseline (preoperatively) and at 1, 7, and 30 days postoperatively.</p><p><strong>Results: </strong>Administration of sarpogrelate via an osmotic pump resulted in significant hearing preservation across all tested frequencies at 1 month post-surgery (P<0.05) compared with the control group, which underwent dummy electrode insertion only. Histological analysis revealed that cochlear fibrosis and inflammatory cell infiltration were markedly reduced in the sarpogrelate-treated groups, especially in the group receiving the higher pump volume. Gene expression analysis supported these findings by showing a significant reduction in inflammation-related markers in the sarpogrelate-treated groups.</p><p><strong>Conclusion: </strong>Sarpogrelate exhibited a protective effect against the loss of residual hearing after CI, likely due to its anti-inflammatory and antifibrotic properties. In addition, the osmotic pump enabled controlled, sustained delivery of the drug over time. These findings indicate that administering sarpogrelate via an osmotic pump represents a promising pharmacological strategy for improving postoperative outcomes in CI patients by preserving residual hearing.</p>","PeriodicalId":10318,"journal":{"name":"Clinical and Experimental Otorhinolaryngology","volume":" ","pages":"254-263"},"PeriodicalIF":3.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400143/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Otorhinolaryngology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21053/ceo.2024.00354","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: This study evaluated the effects of sarpogrelate, a selective 5-hydroxytryptamine (5-HT) 2A receptor antagonist, on the preservation of residual hearing and modulation of inflammatory responses following cochlear implantation (CI) in an animal model.

Methods: The damaging effects of CI were simulated in male albino guinea pigs using a dummy electrode. Animals were allocated to three groups: control (n=12, dummy electrode insertion only), SPG-1004 (n=7, low-capacity pump delivering sarpogrelate), and SPG-2004 (n=6, high-capacity pump delivering sarpogrelate). Sarpogrelate was administered via osmotic pumps at two different volumes, and its effects on hearing thresholds, histological outcomes, and expression of inflammation-related genes were assessed. Hearing was evaluated using auditory brainstem response (ABR) thresholds measured at baseline (preoperatively) and at 1, 7, and 30 days postoperatively.

Results: Administration of sarpogrelate via an osmotic pump resulted in significant hearing preservation across all tested frequencies at 1 month post-surgery (P<0.05) compared with the control group, which underwent dummy electrode insertion only. Histological analysis revealed that cochlear fibrosis and inflammatory cell infiltration were markedly reduced in the sarpogrelate-treated groups, especially in the group receiving the higher pump volume. Gene expression analysis supported these findings by showing a significant reduction in inflammation-related markers in the sarpogrelate-treated groups.

Conclusion: Sarpogrelate exhibited a protective effect against the loss of residual hearing after CI, likely due to its anti-inflammatory and antifibrotic properties. In addition, the osmotic pump enabled controlled, sustained delivery of the drug over time. These findings indicate that administering sarpogrelate via an osmotic pump represents a promising pharmacological strategy for improving postoperative outcomes in CI patients by preserving residual hearing.

Abstract Image

Abstract Image

Abstract Image

耳蜗植入术后经渗透泵输送的沙丁胺醇增强残余听力保存。
目的:本研究在动物模型上评价选择性5-羟色胺(5-HT) 2A受体拮抗剂sarpogreate对人工耳蜗植入(CI)后残余听力保存和炎症反应的影响。方法:采用假电极模拟CI对雄性白化豚鼠的损伤作用。动物分为3组:对照组(n=12,只插入假电极),SPG-1004组(n=7,低容量泵加马尾酸酯)和SPG-2004组(n=6,高容量泵加马尾酸酯)。通过渗透泵以两种不同的体积给药,评估其对听力阈值、组织学结果和炎症相关基因表达的影响。使用听觉脑干反应(ABR)阈值在基线(术前)和术后1、7和30天评估听力。结果:在术后1个月,通过渗透泵给药的sarpogreate对所有测试频率的听力都有显著的保护作用(结论:sarpogreate对CI后残余听力的丧失有保护作用,可能是由于其抗炎和抗纤维化特性。此外,渗透泵的使用允许药物随时间的控制和持续输送。这些发现表明,通过渗透泵给药沙丁鱼酸盐是一种很有前途的药理学方法,可以通过保留残余听力来改善CI患者的术后预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
6.70%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Clinical and Experimental Otorhinolaryngology (Clin Exp Otorhinolaryngol, CEO) is an international peer-reviewed journal on recent developments in diagnosis and treatment of otorhinolaryngology-head and neck surgery and dedicated to the advancement of patient care in ear, nose, throat, head, and neck disorders. This journal publishes original articles relating to both clinical and basic researches, reviews, and clinical trials, encompassing the whole topics of otorhinolaryngology-head and neck surgery. CEO was first issued in 2008 and this journal is published in English four times (the last day of February, May, August, and November) per year by the Korean Society of Otorhinolaryngology-Head and Neck Surgery. The Journal aims at publishing evidence-based, scientifically written articles from different disciplines of otorhinolaryngology field. The readership contains clinical/basic research into current practice in otorhinolaryngology, audiology, speech pathology, head and neck oncology, plastic and reconstructive surgery. The readers are otolaryngologists, head and neck surgeons and oncologists, audiologists, and speech pathologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信